On Dec. 7, 2020, an universal influenza virus vaccine, which produces antibodies that target the part of the surface protein of the influenza virus known to neutralize diverse influenza strains, was described in a study published in the journal Nature Medicine.

This chimeric hemagglutinin (HA)-based vaccine has the potential to provide long-lived protection with two or three immunizations, eliminating the need for revaccination.